A hybrid approach may increase the risk of certain adverse events, according to a new meta-analysis focused on long-term outcomes. 

While GLP-1 drugs were originally developed to treat diabetes, researchers keep finding additional ways these medications can potentially benefit patients.

Cardiovascular disease remains one of the leading causes of mortality in the world, responsible for nearly 20 million deaths in 2022 alone. 

"Although the effectiveness of ADHD medications has been demonstrated ... concerns remain regarding their potential cardiovascular safety," one research explained. 

While the therapy has been successfully tested on animals in the past, this study represents the first time it has been used on humans.

The COVID-19 pandemic undid years and years of progress in terms of preventing CVD-related deaths. What can be done to help reverse this trend once and for all? 

“Going forward, patients and medical teams have a choice of two pathways for chest pain relief: chest pain medication or PCI," one cardiologist said. 

One key difference between this new risk calculator and previous methods is that it does not consider a patient's race or ethnicity. It does, however, consider such factors as where the patient lives, their education and their income level.